<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5011">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01182493</url>
  </required_header>
  <id_info>
    <org_study_id>EUR05 / CEP234</org_study_id>
    <nct_id>NCT01182493</nct_id>
  </id_info>
  <brief_title>OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy</brief_title>
  <acronym>OpT2mise</acronym>
  <official_title>OpT2mise Glucose Control in Type 2 DM With Insulin Pump Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Austria: Ethikkommission</authority>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Czech Republic: Ethics Committee</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <authority>France: Direction Générale de la Santé</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: Institutional Ethics Committee</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Hungary: Research Ethics Medical Committee</authority>
    <authority>Hungary: Scientific and Medical Research Council Ethics Committee</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Italy: National Institute of Health</authority>
    <authority>Macedonia: Ethics Committee</authority>
    <authority>Macedonia: Ministry of Health</authority>
    <authority>Netherlands: Independent Ethics Committee</authority>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Serbia: Ethics Committee</authority>
    <authority>South Africa: Human Research Ethics Committee</authority>
    <authority>South Africa: National Health Research Ethics Council</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the comparative effectiveness of insulin pump
      therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are
      sub optimally controlled with multiple daily injections (MDI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The type of study is interventional post-market release. All the devices under investigation
      have CE mark, and are used within intended use.

      This study has been designed to be prospective randomized controlled with a single-arm
      cross-over in the continuation phase.

      Four hundred type 2 Multiple Daily Injections (MDI) treated patients will undergo a
      screening (run-in) phase of 8 weeks. The aim of the screening phase is to eliminate the
      study effect that might result in a decrease of HbA1c and to make sure that patients, who
      are failing current MDI therapy, are selected.

      After this screening phase, eligible patients will be randomised to receive either
      Continuous Subcutaneous Insulin Infusion (CSII) treatment or continue MDI treatment. The
      first 6-months phase (2-arms parallel) will be followed by another 6-months continuation
      phase (single cross-over of the MDI arm alone switching to CSII).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Between Group Difference in HbA1c When Comparing CSII to MDI</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate change in glycemic control (HbA1c) after 6 months of insulin pump therapy in patients with type 2 DM, as compared to patients on MDI therapy over the same time period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Glycemic Variability</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glycemic parameters calculated from blinded CGM data: Measure of the Average glucose/day; AUC in hypo- (≤70mg/dL) and in hyperglycemia (≥180 mg/dL; Time spent in hypo- (≤70mg/dL) and hyperglycemia (≥180 mg/dL); Mean Amplitude of Glycemic Excursions (MAGE) is the most common measure of the volatility of blood glucose levels; Standard deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months treatment and 6 months follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Severe hypoglycemia incidence; Diabetic Ketoacidosis incidence and Diabetes related hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Postprandial Glycemia</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in mean postprandial hyperglycemia 0 to 2 hours post meal, defined as ≥180 mg/dl and measured by SMBG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Treatment Satisfaction</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight or BMI, Lipids and Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">495</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin Pump Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will get an insulin pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin treatment with MDI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin Pump (Medtronic Minimed Paradigm® VEO)</intervention_name>
    <description>The pump delivers insulin as specified by the patient</description>
    <arm_group_label>Insulin Pump Treatment</arm_group_label>
    <other_name>Medtronic MiniMed Paradigm® VEO system (MMT-554/754</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria at screening:

          1. Diagnosed with type 2 DM, as per Investigator discretion

          2. HbA1c (DCCT-standard) must be ≥ 8.0% and ≤12% as evidenced by central lab value taken
             at screening

          3. Insulin resistance defined as required daily dose between 0.5-1.8 U/Kg or a maximum
             of 220 units of insulin per day

          4. Aged 30 to 75 years old (inclusive)

          5. On MDI regimen (basal/bolus regimen with long-acting insulin and rapid acting
             analogs) defined as ≥ 3 injections per day for at least 3 months prior signing the
             informed consent

          6. Ability to comply with technology, according to Investigator's judgment

          7. Patients must be willing to undergo all study procedures

          8. Female patients of child-bearing potential must be using adequate contraception means
             as assessed by Investigator

        at randomisation:

          1. Diagnosed with type 2 DM, as per Investigator discretion

          2. HbA1c (DCCT-standard) must be ≥ 8.0% and ≤12% as evidenced by central lab value

          3. Insulin resistance defined as required daily dose between 0.7-1.8 U/Kg or a maximum
             of 220 units of insulin per day

          4. On MDI (basal/bolus regimen with long-acting insulin and rapid acting analogs)
             defined as ≥ 3 injections per day

          5. Ability to comply with technology, according to Investigator's judgment

          6. ≥ 2.5 SMBG per day on average, as reported in Carelink clinical during the run-in
             phase.

          7. Patients must be willing to undergo all study procedures

          8. Female patients of child-bearing potential must be using adequate contraception means
             as assessed by Investigator

        Exclusion Criteria :

          1. Subject has a history (≥ 2 events) of hypoglycemic seizure or hypoglycemic coma
             within the last 6 months

          2. Subject is pregnant as assessed by a pregnancy test with central laboratory, or plans
             to become pregnant during the course of the study

          3. Participation in another interventional clinical study, on-going or completed less
             than 3 months prior to signature of Patient Informed Consent.

          4. Subject has proliferative retinopathy or sight threatening maculopathy

          5. Subject has

               -  an acute coronary syndrome (myocardial infarction or unstable angina) within 12
                  months OR

               -  coronary artery revascularization by bypass surgery or stenting within 3 months
                  OR

               -  a transient ischemic attack (TIA) or cerebrovascular accident (CVA) within 3
                  months OR

               -  hospitalization for heart failure within 3 months or current New York Functional
                  Class III or IV OR

               -  current 2nd or 3rd degree heart block OR

               -  symptomatic ventricular rhythm disturbances OR

               -  thromboembolic disease within the last 3 months OR

               -  2nd degree Mobitz type II or 3rd degree heart block

          6. Subject with renal impairment expressed as estimated glomerular filtration rate
             (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula &lt; 30 ml/min as
             demonstrated by the screening central laboratory value at the time of enrollment

          7. Subject has taken oral or injectable steroids within the last 30 days

          8. Systolic blood pressure on screening visit is &gt; 180 mmHg

          9. Diastolic blood pressure on screening visit is &gt; 110 mmHg

         10. Any other disease (eg active cancer under treatment) or condition including
             abnormalities found on the screening tests, that in the opinion of the Investigator,
             may preclude him/her from participating in the study

         11. Taking any medication prescribed for weight loss

         12. Alcohol or drug abuse, other than nicotine, at the investigator's discretion

         13. Use of a GLP-1 agonist or pramlintide (Symlin)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ohad Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center, Tel Hashomer, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ignacio Conget, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICMDM Hospital Clínic i, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Reznic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Côte de Nacre, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronnie Aronson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FRCPC, FACE LMC Endocrinology Centres, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City hopital Vienna-Hieting</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Professor Department of Medicine University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 0M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinologist, 202-301 Columbia Street East</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>416-1033 Davie St</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Science Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Endocrinology Centre</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Centre for Research on Diabetes</name>
      <address>
        <city>Smiths' Falls</city>
        <state>Ontario</state>
        <zip>K7A 4W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hsopital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University, McGill Nutrition and Food Science Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Ste Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik Bad Heilbrunn</name>
      <address>
        <city>Bad Heilbrunn</city>
        <zip>83670</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Diabetes und Gefäßerkrankungen</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Péterfy Hospital and Emergency Center Diabetes Outpatient Clinic</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84105</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetic Clinic</name>
      <address>
        <city>Jerusalem</city>
        <zip>93106</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical center Endocrinology unit</name>
      <address>
        <city>Tel Hashomer - Ramat Gan</city>
        <zip>5262</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf- Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Bari - Policlinico Universitario</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Perugia - Ospedale S.M. Della Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University La Sapienza - Policlinico</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic of Endocrinology</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IJsselland Ziekenhuis Poli Interne geneeskunde</name>
      <address>
        <city>Capelle a/d IJssel</city>
        <zip>2906</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <zip>5600</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Diabetes Research Center</name>
      <address>
        <city>Hoogeveen</city>
        <zip>7900</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Endocrinology, Diabetes and Metabolic Diseases</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Diabetes and Endocrinology</name>
      <address>
        <city>Johannesburg</city>
        <zip>2198</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.Garcjan Podgorski</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICMDM Hospital Clínic i Universitari</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Netherlands</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61037-0/abstract</url>
    <description>Publication of primary endpoints in the Lancet</description>
  </link>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 17, 2016</lastchanged_date>
  <firstreceived_date>August 11, 2010</firstreceived_date>
  <firstreceived_results_date>February 17, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>MDI</keyword>
  <keyword>pump therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>36 hospitals, tertiary care centres, and referal centres participated: eight in Canada, 23 in Europe and Israel, two in South Africa, and three in the USA. The study started in December 2010, and the fi nal data collection date for the primary outcome measure was in February 2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Pump Treatment</title>
          <description>Patients will get an insulin pump
Insulin Pump (Medtronic Minimed Paradigm® VEO): The pump delivers insulin as specified by the patient.</description>
        </group>
        <group group_id="P2">
          <title>Insulin Treatment With MDI</title>
          <description>patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Pump Treatment</title>
          <description>Patients will get an insulin pump
Insulin Pump (Medtronic Minimed Paradigm® VEO): The pump delivers insulin as specified by the patient</description>
        </group>
        <group group_id="B2">
          <title>Insulin Treatment With MDI</title>
          <description>patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="168"/>
                <measurement group_id="B2" value="163"/>
                <measurement group_id="B3" value="331"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="168"/>
                <measurement group_id="B2" value="163"/>
                <measurement group_id="B3" value="331"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55.5" spread="9.7"/>
                <measurement group_id="B2" value="56.4" spread="9.5"/>
                <measurement group_id="B3" value="56.0" spread="9.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="74"/>
                <measurement group_id="B2" value="77"/>
                <measurement group_id="B3" value="151"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="94"/>
                <measurement group_id="B2" value="86"/>
                <measurement group_id="B3" value="180"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.0" spread="0.75"/>
                <measurement group_id="B2" value="9.0" spread="0.75"/>
                <measurement group_id="B3" value="9.0" spread="0.75"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Between Group Difference in HbA1c When Comparing CSII to MDI</title>
        <description>To evaluate change in glycemic control (HbA1c) after 6 months of insulin pump therapy in patients with type 2 DM, as compared to patients on MDI therapy over the same time period</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Insulin Pump Treatment</title>
            <description>Patients will get an insulin pump
Insulin Pump (Medtronic Minimed Paradigm® VEO): The pump delivers insulin as specified by the patient.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Treatment With MDI</title>
            <description>patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="168"/>
                  <measurement group_id="O2" value="163"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Between Group Difference in HbA1c When Comparing CSII to MDI</title>
            <description>To evaluate change in glycemic control (HbA1c) after 6 months of insulin pump therapy in patients with type 2 DM, as compared to patients on MDI therapy over the same time period</description>
            <units>% HbA1c</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" spread="1.2"/>
                  <measurement group_id="O2" value="0.4" spread="1.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycemic Variability</title>
        <description>Glycemic parameters calculated from blinded CGM data: Measure of the Average glucose/day; AUC in hypo- (≤70mg/dL) and in hyperglycemia (≥180 mg/dL; Time spent in hypo- (≤70mg/dL) and hyperglycemia (≥180 mg/dL); Mean Amplitude of Glycemic Excursions (MAGE) is the most common measure of the volatility of blood glucose levels; Standard deviation</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>Severe hypoglycemia incidence; Diabetic Ketoacidosis incidence and Diabetes related hospitalizations</description>
        <time_frame>6 months treatment and 6 months follow-up</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Postprandial Glycemia</title>
        <description>Change in mean postprandial hyperglycemia 0 to 2 hours post meal, defined as ≥180 mg/dl and measured by SMBG</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life and Treatment Satisfaction</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight or BMI, Lipids and Blood Pressure</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Insulin Pump Treatment</title>
          <description>Patients will get an insulin pump
Insulin Pump (Medtronic Minimed Paradigm® VEO): The pump delivers insulin as specified by the patient.</description>
        </group>
        <group group_id="E2">
          <title>Insulin Treatment With MDI</title>
          <description>patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Yves Reznik</name_or_title>
      <organization>CHU Caen</organization>
      <phone>+33231064585</phone>
      <email>reznik-y@chu-caen.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
